Azvudine hydrochloride

• CAT Number: I015022
• CAS Number: 1333126-31-0
• Molecular Formula: C₉H₁₂ClFN₆O₄
• Molecular Weight: 322.68
• Purity: ≥95%
• Target: Reverse Transcriptase
• IUPAC Name: 4-amino-1-[(2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
• InChI: InChI=1S/C9H11FN6O4.ClH/c10-5-6(18)9(3-17,14-15-12)20-7(5)16-2-1-4(11)13-8(16)19;/h1-2,5-7,17-18H,3H2,(H2,11,13,19);1H/t5-,6-,7+,9+;/m0./s1
• InChIKey: MKMLHJHSIBILJH-DBSFTZRASA-N
• SMILES: C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@](O2)(CO)N=[N+]=[N-])O)F.Cl

Azvudine hydrochloride（Cat No.:I015022）is a nucleoside analog with potent antiviral properties, primarily investigated for its activity against RNA viruses, including HIV and hepatitis C. It acts by inhibiting viral RNA-dependent RNA polymerase, disrupting viral replication. With its unique mechanism and broad-spectrum efficacy, Azvudine hydrochloride is a valuable tool in virology research, particularly in studying viral life cycles and resistance mechanisms. Its application in pharmaceutical studies also extends to exploring novel antiviral therapies, highlighting its potential as a promising candidate in the development of effective antiviral drugs.

Reference

[1]. Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617.